drugset / Trial / NCT04897503

Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose

NCT04897503

Phase 3 Unknown 170 enrolled Cornea and Laser Eye Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is being conducted to evaluate the safety and efficacy of isotonic riboflavin for corneal collagen crosslinking for keratoconus and corneal ectasia. will determine the safety and efficacy of corneal collagen crosslinking (CXL) performed with two different riboflavin formulations for reducing corneal curvature.

Timeline

Start
2021-04-16
Primary completion
2025-06
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Riboflavin Other / unclassified 0.1 % Other